News

Filter by year:

Filter by tags:

9/09/2021

iECURE, co-founded by GTP's Dr. Jim Wilson, Launches With $50 Million Series A Financing to Develop In Vivo Gene Insertion Approaches for Devastating Diseases

iECURE, a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet need, announced it has closed a $50 million Series A financing led by Versant Ventures and OrbiMed Advisors. The funds will be used to advance iECURE’s pipeline of up to 13 programs, all of which benefit from gene editing and in vivo delivery approaches being developed in the laboratory of James Wilson, M.D., Ph.D., of the University of Pennsylvania Gene Therapy Program (GTP).

9/07/2021

Moderna and the Institute for Life Changing Medicines Announce a New Collaboration to Develop an mRNA Therapeutic for Ultra-Rare Disease, Crigler-Najjar Syndrome Type 1

Moderna, Inc. and the Institute for Life Changing Medicines announced a new collaboration to develop a new mRNA therapeutic for Crigler-Najjar Syndrome Type 1, an ultra-rare disease. The goal of the collaboration is to make an mRNA therapy for the treatment of CN-1 available at no cost to patients.

9/02/2021

GTP's Dr. Jim Wilson and Alex Karnal Establish the Nonprofit, Institute for Life Changing Medicines, to Identify and Develop Next Generation Medicines for Rare Diseases

Dr. Jim Wilson and Alex Karnal announced the launch of The Institute for Life Changing Medicines, a nonprofit organization with a mission of identifying, developing and promoting access to therapies that have transformative potential but are not considered commercially viable because they are designed to treat small populations of patients suffering from rare diseases.

8/06/2021

GTP Announces the Publication of a Manuscript Developed in Collaboration with Luk Vandenberghe’s Laboratory at Harvard Medical School

The SARS-CoV-2 pandemic has affected more than 185 million people worldwide resulting in over 4 million deaths. To contain the pandemic, there is a continued need for safe vaccines that provide durable protection at low and scalable doses and are easily delivered. Here, AAVCOVID-1, an adeno-associated viral (AAV), Spike gene-based vaccine candidate demonstrates potent immunogenicity in mouse and nonhuman primates following a single injection and confers complete protection from SARS-CoV-2 challenge in macaques.

8/05/2021

GTP Announces Expanded Strategic Collaboration with Passage Bio to Advance Genetic Medicines, Initially Focused on Alzheimer’s Disease and Temporal Lobe Epilepsy

The Gene Therapy Program at the University of Pennsylvania's expanded strategic collaboration and license agreement with Passage Bio establishes new research programs to discover and develop new genetic medicines for Alzheimer’s Disease and Temporal Lobe Epilepsy as well as additional large CNS indications upon mutual agreement. These new programs include a collaborative initial discovery phase focused on identifying relevant biological targets for these two diseases.

7/15/2021

GTP manuscript focusing on a novel approach to prevent infection by SARS-CoV-2 variants published in PLOS Pathogens

SARS-CoV-2 variants have emerged with enhanced pathogenicity and transmissibility, and escape from pre-existing immunity, suggesting first-generation vaccines and monoclonal antibodies may now be less effective. Here we present an approach for preventing clinical sequelae and the spread of SARS-CoV-2 variants.